Clinical case of treatment of a patient with metastatic colorectal cancer with a POLE-mutation
Abstract
Introduction. Metastatic colorectal cancer remains one of the major challenges in modern oncology due to its high incidence, frequent diagnosis at advanced stages, and the limited efficacy of standard lines of systemic therapy. In recent years, molecular genetic profiling of tumors has become increasingly important, enabling individualized selection of anticancer treatment. Mutations in the POLE gene are considered one of the potential biomarkers of sensitivity to immunotherapy. However, the clinical significance of individual POLE mutation variants remains ambiguous. Aim. To analyze a clinical case of treatment of a female patient with metastatic colorectal cancer and an identified POLE c.871G>A (p.Asp291Asn) mutation, with an assessment of the efficacy of PD-1 inhibitor immunotherapy. Materials and methods. This article presents a clinical observation of a female patient born in 1954 with stage IV sigmoid colon cancer and metastatic involvement of the liver, retroperitoneal lymph nodes, lungs, and mediastinal lymph nodes. The patient’s medical history, morphological and molecular genetic findings, sequence of systemic anticancer therapy, treatment tolerability, and clinical outcome were analyzed. Results. The patient sequentially received first-line systemic anticancer therapy with the XELOX regimen, followed by second-line therapy with cetuximab in combination with FOLFIRI and subsequent maintenance therapy with cetuximab plus de Gramont. Molecular genetic testing revealed no KRAS, NRAS, or BRAF mutations, no evidence of MSI, and no HER2 amplification; additionally, a POLE c.871G>A (p.Asp291Asn) mutation was detected. Due to disease progression, third-line immunotherapy with nivolumab was initiated. During treatment, disease stabilization was observed according to RECIST 1.1 criteria; however, a tendency toward growth of metastatic lesions persisted. Therapy was complicated by adverse events, including dermatologic toxicity, anemia, dyspeptic symptoms, and progression of chronic kidney disease to stage 4, which required discontinuation of the drug. Conclusion. The presented clinical case demonstrates that the presence of the POLE c.871G>A (p.Asp291Asn) mutation alone cannot be considered sufficient grounds for predicting the efficacy of immunotherapy in metastatic colorectal cancer. This variant is likely not among the functionally significant POLE mutations associated with ultrahigh tumor mutational burden and a pronounced response to immune checkpoint inhibitors. These findings highlight the need for comprehensive interpretation of POLE mutations, taking into account their functional significance, MSI status, TMB level, and clinical context before immunotherapy is prescribed.